NFIL3 and breast cancer: Sostdc1 was also frequently downregulated in primary breast cancers (98.2%), and Sostdc1 promoter hypermethylation at CpG sites inhibited cell proliferation and survival, while E4BP4 reduced Sostdc1 expression and its promoter activity in breast cancer cells (Rawat et al., 2014).